Car-T, TIL news | ZIOP Message Board Posts

ZIOPHARM Oncology, Inc.

  ZIOP website

ZIOP   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  112739 of 113343  at  2/26/2020 8:53:21 PM  by

vorlon1966


 In response to msg 112697 by  MarkC
view thread

Re: Car-T, TIL news

True...but the kicker is whether or not the TILs are reacting to all the cancer antigens in the tumor. His approach is sound but may be incomplete. In solid tumors the level of mutations due to hypoxia is not necessarily the same. Itís why solid tumors have more than one mutation. Deeper in the tumor the greater the hypoxia and thus the different mutations to deal with cell self survival in dealing with that different lack of oxygen levels.

PVCT has a patent on a further approach but not yet a clinical study. In their patent they kill off the whole tumor by PV-10 ablation ...,releasing all cancer antigens and then sample the TILís to be cloned ex vivo before re-injecting as a type of vaccine. This will become a future trial. The logic is sound. In order to have been awarded that patent they would have had to show efficacy in a preclinical study....you canít get a patent now on just an idea...you have to show proof of the concept.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 106
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
112762 Re: Car-T, TIL news dnmun 1 2/27/2020 12:56:23 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...